Logo image of PETS

PETMED EXPRESS INC (PETS) Stock Fundamental Analysis

NASDAQ:PETS - Nasdaq - US7163821066 - Common Stock - Currency: USD

3.66  -0.14 (-3.68%)

Fundamental Rating

4

PETS gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 121 industry peers in the Specialty Retail industry. While PETS has a great health rating, there are worries on its profitability. PETS does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

3

1. Profitability

1.1 Basic Checks

PETS had positive earnings in the past year.
PETS had a positive operating cash flow in the past year.
Of the past 5 years PETS 4 years were profitable.
Each year in the past 5 years PETS had a positive operating cash flow.
PETS Yearly Net Income VS EBIT VS OCF VS FCFPETS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M

1.2 Ratios

Looking at the Return On Assets, with a value of 0.25%, PETS is in line with its industry, outperforming 47.93% of the companies in the same industry.
PETS has a Return On Equity of 0.37%. This is comparable to the rest of the industry: PETS outperforms 52.07% of its industry peers.
The Return On Invested Capital of PETS (1.24%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA 0.25%
ROE 0.37%
ROIC 1.24%
ROA(3y)2.57%
ROA(5y)8.14%
ROE(3y)2.43%
ROE(5y)9.77%
ROIC(3y)N/A
ROIC(5y)N/A
PETS Yearly ROA, ROE, ROICPETS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 20 30

1.3 Margins

PETS has a Profit Margin of 0.14%. This is comparable to the rest of the industry: PETS outperforms 47.11% of its industry peers.
Looking at the Operating Margin, with a value of 0.62%, PETS is doing worse than 62.81% of the companies in the same industry.
With a Gross Margin value of 27.68%, PETS is not doing good in the industry: 71.07% of the companies in the same industry are doing better.
In the last couple of years the Gross Margin of PETS has declined.
Industry RankSector Rank
OM 0.62%
PM (TTM) 0.14%
GM 27.68%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.27%
GM growth 5Y-3.61%
PETS Yearly Profit, Operating, Gross MarginsPETS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 20 30

7

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so PETS is destroying value.
The number of shares outstanding for PETS has been increased compared to 1 year ago.
PETS has more shares outstanding than it did 5 years ago.
There is no outstanding debt for PETS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
PETS Yearly Shares OutstandingPETS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
PETS Yearly Total Debt VS Total AssetsPETS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

An Altman-Z score of 3.63 indicates that PETS is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 3.63, PETS belongs to the best of the industry, outperforming 80.99% of the companies in the same industry.
There is no outstanding debt for PETS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 3.63
ROIC/WACC0.13
WACC9.86%
PETS Yearly LT Debt VS Equity VS FCFPETS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

PETS has a Current Ratio of 1.43. This is a normal value and indicates that PETS is financially healthy and should not expect problems in meeting its short term obligations.
PETS has a Current ratio of 1.43. This is comparable to the rest of the industry: PETS outperforms 51.24% of its industry peers.
A Quick Ratio of 1.18 indicates that PETS should not have too much problems paying its short term obligations.
PETS's Quick ratio of 1.18 is fine compared to the rest of the industry. PETS outperforms 77.69% of its industry peers.
Industry RankSector Rank
Current Ratio 1.43
Quick Ratio 1.18
PETS Yearly Current Assets VS Current LiabilitesPETS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2

3. Growth

3.1 Past

PETS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 102.56%, which is quite impressive.
PETS shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -10.82%.
PETS shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -0.17% yearly.
EPS 1Y (TTM)102.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%70%
Revenue 1Y (TTM)-10.82%
Revenue growth 3Y-3.13%
Revenue growth 5Y-0.17%
Sales Q2Q%-18.88%

3.2 Future

PETS is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 29.72% yearly.
The Revenue is expected to decrease by -7.74% on average over the next years.
EPS Next Y153.62%
EPS Next 2Y34.31%
EPS Next 3Y29.72%
EPS Next 5YN/A
Revenue Next Year-17.16%
Revenue Next 2Y-9.97%
Revenue Next 3Y-7.74%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
PETS Yearly Revenue VS EstimatesPETS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 100M 200M 300M
PETS Yearly EPS VS EstimatesPETS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 0.5 1 1.5 2

2

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 366.00, PETS can be considered very expensive at the moment.
Compared to the rest of the industry, the Price/Earnings ratio of PETS indicates a slightly more expensive valuation: PETS is more expensive than 61.98% of the companies listed in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 25.91, PETS is valued quite expensively.
PETS is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE 366
Fwd PE N/A
PETS Price Earnings VS Forward Price EarningsPETS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 100 200 300

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of PETS indicates a rather cheap valuation: PETS is cheaper than 90.08% of the companies listed in the same industry.
The rest of the industry has a similar Price/Free Cash Flow ratio as PETS.
Industry RankSector Rank
P/FCF 88.44
EV/EBITDA 3.39
PETS Per share dataPETS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8 10

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates PETS does not grow enough to justify the current Price/Earnings ratio.
PETS's earnings are expected to grow with 29.72% in the coming years. This may justify a more expensive valuation.
PEG (NY)2.38
PEG (5Y)N/A
EPS Next 2Y34.31%
EPS Next 3Y29.72%

0

5. Dividend

5.1 Amount

PETS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

PETMED EXPRESS INC

NASDAQ:PETS (5/23/2025, 11:47:40 AM)

3.66

-0.14 (-3.68%)

Chartmill FA Rating
GICS SectorConsumer Discretionary
GICS IndustryGroupConsumer Discretionary Distribution & Retail
GICS IndustrySpecialty Retail
Earnings (Last)05-12 2025-05-12/amc
Earnings (Next)08-04 2025-08-04
Inst Owners44.55%
Inst Owner Change-10.94%
Ins Owners8.21%
Ins Owner Change12.17%
Market Cap75.62M
Analysts42.86
Price Target3.67 (0.27%)
Short Float %10.04%
Short Ratio8.11
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0.59
Dividend Growth(5Y)-11.13%
DP54.34%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-96.08%
Min EPS beat(2)-488.23%
Max EPS beat(2)296.08%
EPS beat(4)2
Avg EPS beat(4)-36.55%
Min EPS beat(4)-488.23%
Max EPS beat(4)296.08%
EPS beat(8)3
Avg EPS beat(8)-169.93%
EPS beat(12)4
Avg EPS beat(12)-128.55%
EPS beat(16)4
Avg EPS beat(16)-101.84%
Revenue beat(2)0
Avg Revenue beat(2)-12.18%
Min Revenue beat(2)-12.84%
Max Revenue beat(2)-11.51%
Revenue beat(4)1
Avg Revenue beat(4)-8.81%
Min Revenue beat(4)-12.84%
Max Revenue beat(4)0.31%
Revenue beat(8)1
Avg Revenue beat(8)-6.94%
Revenue beat(12)1
Avg Revenue beat(12)-6.81%
Revenue beat(16)1
Avg Revenue beat(16)-6.96%
PT rev (1m)-4%
PT rev (3m)-4%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-10.07%
Valuation
Industry RankSector Rank
PE 366
Fwd PE N/A
P/S 0.31
P/FCF 88.44
P/OCF 15.65
P/B 0.79
P/tB 1.39
EV/EBITDA 3.39
EPS(TTM)0.01
EY0.27%
EPS(NY)-0.08
Fwd EYN/A
FCF(TTM)0.04
FCFY1.13%
OCF(TTM)0.23
OCFY6.39%
SpS11.96
BVpS4.66
TBVpS2.64
PEG (NY)2.38
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 0.25%
ROE 0.37%
ROCE 1.57%
ROIC 1.24%
ROICexc 2.57%
ROICexgc 23.86%
OM 0.62%
PM (TTM) 0.14%
GM 27.68%
FCFM 0.35%
ROA(3y)2.57%
ROA(5y)8.14%
ROE(3y)2.43%
ROE(5y)9.77%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.27%
GM growth 5Y-3.61%
F-Score7
Asset Turnover1.71
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 57.96%
Cap/Sales 1.61%
Interest Coverage 250
Cash Conversion 57.63%
Profit Quality 239.5%
Current Ratio 1.43
Quick Ratio 1.18
Altman-Z 3.63
F-Score7
WACC9.86%
ROIC/WACC0.13
Cap/Depr(3y)91.99%
Cap/Depr(5y)95.64%
Cap/Sales(3y)1.43%
Cap/Sales(5y)1.18%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)102.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%70%
EPS Next Y153.62%
EPS Next 2Y34.31%
EPS Next 3Y29.72%
EPS Next 5YN/A
Revenue 1Y (TTM)-10.82%
Revenue growth 3Y-3.13%
Revenue growth 5Y-0.17%
Sales Q2Q%-18.88%
Revenue Next Year-17.16%
Revenue Next 2Y-9.97%
Revenue Next 3Y-7.74%
Revenue Next 5YN/A
EBIT growth 1Y111.94%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year161.4%
EBIT Next 3Y51.6%
EBIT Next 5YN/A
FCF growth 1Y-96.28%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-81.97%
OCF growth 3Y-52.42%
OCF growth 5Y-37.46%